Dataset Information

BRD4 degradation via stabilization of a native interaction with DCAF16

ABSTRACT: Targeted protein degradation is a modality based on small molecules that induce proximity between a protein of interest (POI) and an E3 ubiquitin ligase, thus prompting POI ubiquitination and degradation. To expand the reach of TPD, current research is geared to unlock novel E3s. To that end, the transcriptional co-activator protein BRD4 has emerged as a frequently used POI. Derivatization of known BRD4 ligands with structurally diverse substituents has yielded a suite of potent BRD4 degraders, thus generating the notion that BRD4 is particularly amenable to TPD. Here, we mechanistically characterize two BRD4 degraders via orthogonal CRISPR screens. Despite their structural dissimilarity, both degraders functionally converge on a unifying mechanism of action that involves the CRL4DCAF16 ligase complex. Using recombinant reconstitution, as well as biophysical and structural elucidation, we demonstrate that BRD4 has an intrinsic activity for DCAF16, which is further enhanced by both compounds. We uncover a novel mode of molecular recognition based on multivalent "gluing" of BRD4 onto DCAF16 that requires both bromodomains of BRD4. Our data thus imply a substantial conceptual overlap between PROTACs and molecular glue degraders, and highlight multivalency as a novel concept in the design of proximity-inducing drugs.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Andrea Rukavina

LAB HEAD: Georg Winter

PROVIDER: PXD040570 | Pride | 2024-01-08

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	CC_GW_166_P12921_M1123-1-TMTpro15-36F-MS2quant-OTOT-TotalPepNorm-ANOVAprotAbund-AR-20221109.mgf	Mgf
	CC_GW_166_P12921_M1123-1-TMTpro15-36F-MS2quant-OTOT-TotalPepNorm-ANOVAprotAbund-AR-20221109.mzML	Mzml
	CC_GW_166_P12921_M1123-1-TMTpro15-36F-MS2quant-OTOT-TotalPepNorm-ANOVAprotAbund-AR-20221109.mzid.gz	Mzid
	CC_GW_166_P12921_M1123-1.raw	Raw
	CC_GW_166_P12921_M1123-10.raw	Raw

Items per page:

1 - 5 of 39

Publications

Targeted protein degradation via intramolecular bivalent glues.

Hsia Oliver O Hinterndorfer Matthias M Cowan Angus D AD Iso Kentaro K Ishida Tasuku T Sundaramoorthy Ramasubramanian R Nakasone Mark A MA Imrichova Hana H Schätz Caroline C Rukavina Andrea A Husnjak Koraljka K Wegner Martin M Correa-Sáez Alejandro A Craigon Conner C Casement Ryan R Maniaci Chiara C Testa Andrea A Kaulich Manuel M Dikic Ivan I Winter Georg E GE Ciulli Alessio A

Nature 20240221 8002

Targeted protein degradation is a pharmacological modality that is based on the induced proximity of an E3 ubiquitin ligase and a target protein to promote target ubiquitination and proteasomal degradation. This has been achieved either via proteolysis-targeting chimeras (PROTACs)-bifunctional compounds composed of two separate moieties that individually bind the target and E3 ligase, or via molecular glues that monovalently bind either the ligase or the target<sup>1-4</sup>. Here, using orthogo ...[more]

PMID: 38383787

Similar Datasets

Project description:The histone acetyl-reader BRD4 is an important regulator of chromatin structure and transcription, yet factors modulating its activity have remained elusive. Here we describe two complementary screens for genetic and physical interactors of BRD4, which converge on the folate pathway enzyme MTHFD1. We show that a fraction of MTHFD1 resides in the nucleus, where it is recruited to distinct genomic loci by direct interaction with BRD4. Inhibition of either BRD4 or MTHFD1 results in similar changes in nuclear metabolite composition and gene expression, and pharmacologic inhibitors of the two pathways synergize to impair cancer cell viability in vitro and in vivo. Our finding that MTHFD1 and other metabolic enzymes are chromatin-associated suggests a direct role for nuclear metabolism in the control of gene expression. BRD4 is an important chromatin regulator with roles in gene regulation, DNA damage, cell proliferation and cancer progression1-4. The protein is recruited to distinct genomic loci by the interaction of its tandem bromodomains with acetylated lysines on histones and other nuclear proteins5. There, BRD4 acts as a transcriptional activator by P-TEFb-mediated stimulation of transcriptional elongation6. The activating function of BRD4 on key driver oncogenes like MYC have made this epigenetic enzyme an important therapeutic target in both BRD4 translocated and BRD4 wild-type cancers3,7-12, and at least seven bromodomain inhibitors have reached the clinical stage13. Genome-wide studies have identified the role of BRD4-induced epigenetic heterogeneity in cancer cell resistance14, and factors defining BRD4 inhibitor response15,16. However, despite its clinical importance and the broad role of BRD4 in chromatin organization, surprisingly little is known about factors that are directly required for BRD4 function. To systematically expand the list of known BRD4 interactors5 and to characterize proteins directly required for BRD4 function, we developed a strategy of two complementary screens for genetic and physical partners of BRD4. The two approaches converge on a single factor, methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). Our description of a transcriptional role for this C-1-tetrahydrofolate synthase highlights a direct connection between nuclear folate metabolism and cancer regulation.